10 Biggest Price Target Changes For Monday
18 Oct 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Barclays reduced the price target for The Walt Disney Company (NYSE: DIS) from $210 to $175. Disney shares fell 1.6% to $173.60 in pre-market trading.
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
18 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, General
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.
Why Are Ocular Therapeutix Shares Trading Higher Today?
11 Oct 21
Biotech, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
Ocular Therapeutix Announces FDA Approval Of Supplemental New Drug Application For DEXTENZA 0.4 mg For Intracanalicular Use For Treatment Of Ocular Itching Associated With Allergic Conjunctivitis
11 Oct 21
News, FDA, Movers, Trading Ideas
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.S.
28 Stocks Moving In Monday's Mid-Day Session
11 Oct 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
1 Oct 21
Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, Top Stories, General
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned.
HC Wainwright & Co. Upgrades Ocular Therapeutix to Buy, Announces $17 Price Target
10 Aug 21
News, Upgrades, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Yi Chen upgrades Ocular Therapeutix (NASDAQ:OCUL) from Neutral to Buy and announces $17 price target.
Earnings Scheduled For August 9, 2021
9 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
8 Aug 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
6 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, IPOs, Top Stories
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)